"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Chen X, Wu B, Perera HA, Yan M. Synthesis of Glycopolymer Micelles for Antibiotic Delivery. Molecules. 2023 May 11; 28(10).
-
Henrikson CA, Sohail MR, Acosta H, Johnson EE, Rosenthal L, Pachulski R, Dan D, Paladino W, Khairallah FS, Gleed K, Hanna I, Cheng A, Lexcen DR, Simons GR. Antibacterial Envelope Is Associated With?Low Infection Rates After Implantable Cardioverter-Defibrillator and?Cardiac Resynchronization Therapy Device Replacement: Results of the Citadel and Centurion Studies. JACC Clin Electrophysiol. 2017 10; 3(10):1158-1167.
-
Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis. 2016 06 01; 16:242.
-
Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, Dupont WD, Chelimsky T, Galpern WR. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Mar; 13(3):268-75.
-
Yang S, Makredes M, O'Donnell P, Levin NA. A case of Hansen Disease presenting as tinea versicolor. Dermatol Online J. 2013 Apr 15; 19(4):7.
-
Matheos T, Walz JM, Adams JP, Johnson K, Longtine K, Longtine J, O'Neill M, Heard SO. Comparison of the duration of antimicrobial activity of 2 different antimicrobial central venous catheters. Infect Control Hosp Epidemiol. 2010 Mar; 31(3):295-7.
-
Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis. 2009 Aug 01; 49(3):424-7.
-
Marcus DV, Mahmoud BH, Hamzavi IH. Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy. Arch Dermatol. 2009 Jul; 145(7):787-9.
-
Kornfeld H. An ounce of tuberculosis prevention. Chest. 2008 Apr; 133(4):835-6.
-
Calmann MA, Marinus MG. Differential effects of cisplatin and MNNG on dna mutants of Escherichia coli. Mutat Res. 2005 Oct 15; 578(1-2):406-16.